<img src="/media/1098/mrbt_h_bk.svg" style="max-width:200px; margin-bottom:10px; display:block;" />MRBT Maintenance Drugs list

Maintenance drugs* that are subject to the new dispensing fee limits (effective January 1, 2021) generally fall into the following categories: 

Treatment categories Drug examples**

Stomach acid related disorders

omeprazole, pantoprazole, ranitidine


metformin, gliclazide, linagliptin

Common heart conditions

ramipril, atorvastatin, metoprolol, rivaroxaban

Hormone replacement therapy

estradiol, conjugated estrogen, progesterone


alendronate, risedronate, raloxifene

Depression and anxiety

citalopram, amitriptyline, venlafaxine

Bladder conditions

oxybutynin, tolterodine

Benign prostatic hyperplasia

finasteride, tamsulosin

Thyroid conditions

levothyroxine, methimazole

Gout therapy

allopurinol, febuxostat, colchicine

Chronic inflammatory conditions

methotrexate, leflunomide, mesalazine

Chronic lung conditions

theophylline, montelukast, roflumilast

*Solid-oral dosage forms (tablets and capsules) only; limits do not apply for non-solid oral medications (i.e. liquids, inhalers, compounds, injectables).

**This is not an exhaustive list of specific medications impacted in each category.


Dispensing fees for solid-oral drugs included on the Maintenance Drug list will be limited to five per year. All other solid-oral medications (tablets and capsules) used to treat chronic conditions will be limited to 13 dispensing fees per calendar year.